Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
Following the termination of the GENERATION HD1 trial in March 2021, Roche have now announced plans for a new Phase…
The first interim data has been published from a Phase I/II trial testing the safety and tolerability of AMT-130. If…
Huntington’s disease (HD) is an autosomal dominant inherited neurodegenerative disease caused by a CAG trinucleotide repeat expansion in the huntingtin…